secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0001933414-25-000057
Event type: earnings
Sentiment:  positive
Materiality: 0.88
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys reports positive pivotal trial results; Q1 net loss $42.2M; cash $343M
--------------------------------------------------------------------------------

- Launch-HTN: 50 mg lorundrostat achieved 9.1 mmHg placebo-adjusted SBP reduction at week 6 (p<0.0001).
- Advance-HTN: 50 mg cohort met primary endpoint; 7.9 mmHg placebo-adjusted SBP reduction (p=0.001).
- Cash, equivalents and investments $343.0M as of March 31, 2025, vs $198.2M at Dec 31, 2024.
- Net loss for Q1 2025 was $42.2M, up from $31.5M in Q1 2024; R&D expenses rose to $37.9M.
- Appointed Eric Warren as Chief Commercial Officer; pre-NDA meeting with FDA expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/0001933414-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341425000057/mlys-20250512.htm
  HTML page:      https://secwatch.observer/filing/0001933414-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer